继发性磺脲类药物失效与成人迟发型自身免疫性糖尿病的关系

目的 :通过测定 2型糖尿病中继发性磺脲类药物失效 (SFS)患者的谷氨酸脱羧酶抗体 (GAD Ab) ,探讨SFS与成人迟发型自身免疫性糖尿病 (LADA)的关系。方法 :对 178例SFS患者进行空腹血糖、餐后 2小时血糖、空腹C肽、餐后 2小时C肽、GAD Ab、糖化血红蛋白 (HbA1c)进行测定。结果 :178例SFS患者GAD Ab阳性者 3 4例 ,阳性率 19 10 %。GAD Ab阳性的病人与GAD Ab阴性的病人相比 ,二者发病时的空腹血糖差别不大 ,前者发病年龄较轻 ,体重指数较低 ,空腹及餐后 2小时C肽水平也明显低于后者。GAD Ab阳性患者的餐后 2小时血糖、HbAlc明显高于GAD Ab阴性者 ,说明近 2～ 3个月内病人的血糖总体控制情况较差。结论 :原来诊断为 2型糖尿病而后出现SFS的患者其实有一部分为LADA。表明LADA是 2型糖尿病患者出现SFS的原因之一 ,SFS的原因可能还包含自身免疫因素的参与     

1型糖尿病患者中胰岛B细胞特异性锌转运蛋白自身抗体检测标准的建立

目的建立1型糖尿病（Type 1 diabetes,T1DM）患者中一种新的自身抗体即锌转运蛋白8自身抗体（ZnT8-Ab）检测标准,并应用于临床上T1DM的预测与诊断。方法采用放射免疫沉淀法检测T1DM患者中ZnT8-Ab的阳性率,结果用ZnT8-Ab指数来表示。以102名健康对照组ZnT8-Ab指数的99．5％百分位点作为正常上限,检测106例T1DM和126例2型糖尿病（T2DM）患者血清中ZnT8．Ab水平滴度。结果该改进的放射免疫沉淀法批内变异系数（CV）为4．8％-10．7％,批间CV为3．9％-14．1％,阳性临界值为0．015,结果判断重复性为100％,用该方法检测T1DM患者ZnT8．Ab阳性率为39．6％（42／106）,T2DM患者为1．6％（2／126）,正常人为1．0％（1／102）,P〈0．001,结果具有显著性差异。结论此种放射免疫沉淀法检测ZnT8．Ab,其灵敏度高,特异性强,可用来预测以及诊断T1DM,结合糖尿病其它自身抗体可提高T1DM和IADA患者的检出率,可在临床上广泛应用。     

糖尿病患者血清ICA、IAA、GAD-Ab、IA-2-Ab的检测及临床意义

为了探讨ICA、IAA、GAD Ab、IA 2 Ab对糖尿病患者的检测及临床意义 ,用ELISA测定 15 5例 1型糖尿病患者和 4 4例2型糖尿病患者以及 32例正常人血清中的ICA、IAA、GAD、IA 2 A6。结果　 1型糖尿病组和 2型糖尿病组ICA的阳性率分别为 36 .8%和 11.4 % ,IAA的阳性率分别为 2 3.2 %和 16 .0 % ,GAD Ab的阳性率分别为 5 8.7%和 16 .0 % ,IA 2 Ab的阳性率分别为 2 0 .0 %和 6 .8%。结果表明 ,ICA、IAA、GAD、IA 2抗体在 1型糖尿病的早期诊断及预测有重要的临床意义 ,且联合测定以上抗体能提高检出率 ,避免漏诊。糖尿病患…     

免疫印迹法与放射免疫法检测抗谷氨酸脱羧酶抗体结果的比较

目的：比较免疫印迹法和放射免疫法测定抗谷氨酸脱羧酶抗体（GAD‐Ab）的结果。方法分别采用免疫印迹法和放射免疫法检测50例2型糖尿病（T2DM）患者和50例健康对照者血清中的GAD‐Ab。结果免疫印迹法检测GAD‐Ab的灵敏度为6％，特异度为100％，放射免疫分析检测GAD‐Ab的灵敏度为20％，特异度为98％。2种方法灵敏度差异有统计学意义（P＜0．05），但特异度差异无统计学意义（P＞0．05）。结论不同的方法学之间，检测结果差异较大，临床医生应结合患者临床表现及其他检查项目综合分析做出正确的判断。     

谷氨酸脱羧酶抗体和蛋白酪氨酸磷酸酶抗体检测的标准化研究

目的研究谷氨酸脱羧酶抗体(GAD—Ab)和蛋白酪氨酸磷酸酶-2抗体(IA-2A)检测的标准化，为合理选择检测方法及准确判定结果提供依据。方法应用国际糖尿病免疫学会(IDS)推荐的WHO单位制，采用放射配体法检测125名健康人的GAD—Ab和IA-2A以确定阳性判断标准，通过检测IDS第3次糖尿病自身抗体标准化检测方法评估(DASP 2003)工作组提供的100名健康对照及50例新发1型糖尿病患者血清，验证其灵敏度与特异性。并采用新一代的ELISA试剂盒检测41例已知抗体滴度的标本，对比ELISA与标化后放射配体法的一致性。结果GAD—Ab的阳性阈值为18．5U／ml，IA-2A为2．7U／ml。DASP 2003反馈结果显示，本室GAD—Ab检测的灵敏度82％，特异性98％；IA-2A检测的灵敏度64％，特异性100％；受试者工作特征(ROC)曲线分析显示，本室GAD-Ab曲线下面积(AUC)以及统一按95％特异性标化后的灵敏度(AS95)分别为0．946％及86％，IA-2A分别为0．824％及68％。在52个回报结果的实验室中综合排名第15位。ELISA试剂盒与标化后的放射配体法检测GAD—Ab的一致率82．9％，Kappa值0．656；检测IA-2A的一致率75．6％，Kappa值0．514；结果判定不一致者多集中在阳性边缘水平的标本中。结论经标准化后的GAD—Ab和IA-2A放射配体法灵敏度和特异性明显提高；新一代ELISA试剂盒检测GAD—Ab和IA-2A可应用于临床，但对于检测结果阴性而临床可疑者，建议采用放射配体检测法核实。     

时间分辨荧光免疫分析技术检测乙肝病毒标志物优越性的探讨

目的建立时间分辨荧光免疫分析法(TRFIA)检测乙肝病毒标志物5项指标的方法,并与酶联免疫吸附试验(ELISA)进行比较分析。评价TRFIA的性能,以期提高乙肝病毒标志物定量检测的诊断价值。方法收集329份血清标本,用TRFIA检测乙肝病毒标志物,并与ELISA检测的结果进行比较分析。结果两种方法检测乙肝病毒标志物的结果一致率较好[乙肝表面抗原(HBs Ag)为99.4%,乙肝表面抗体(HBs Ab)为98.8%,乙肝E抗原(HBe Ag)为99.1%,乙肝E抗体(HBe Ab)为98.2%,乙肝核心抗体(HBc Ab)为97.6%];TRFIA阳性检出率大于ELISA(HBs Ag:90比88,HBs Ab:115比111,HBe Ag:45比42,HBe Ab:211比205,HBc Ab:246比238,P均0.05)。TRFIA的敏感度和特异度均优于ELISA(敏感度:97.80%比91.21%,特异度:99.58%比97.89%,P均0.05);TRFIA的批内和批间变异系数(CV)均优于ELISA(批内CV:3.19%比5.99%,批间CV:4.68%比7.55%,P均0.05)。结论 TRFIA作为一项具有巨大发展潜力的新兴生物技术,对乙肝病毒标志物的检测效能高于ELISA。     

成人糖尿病3种自身抗体检测的临床分析

目的 分析探讨谷氨酸脱羧酶抗体（GAD—Ab）、胰岛细胞抗体（ICA）、胰岛素抗体（IAA）的检测对成人糖尿病的诊断价值和选择治疗方案的指导意义。方法 定性酶联免疫吸附试验（ELISA）检测自身抗体，放免法检测胰岛素和C-肽。结果 468例成人糖尿病患者GAD—Ab阳性130例，阳性率27．8％，ICA阳性共89例，阳性率19．0％，IAA的阳性144例，阳性率30．8％，GAD—Ab、IAA、ICA三者同时阳性14例，阳性率3．1％．分别随机抽查了GAD—Ab或ICA阳性和3种抗体阴性各50例患者的空腹及给予100克葡萄糖2小时后的胰岛素和C-肽含量，比较差异无显著性意义，P〉0．05。结论 成人糖尿患者及时检测GAD-Ab、IAA、ICA对临床糖尿病的分型和治疗方案选择有重要意义。     

糖尿病患者血清ICA、IAA、GAD-Ab、IA-2-Ab的检测及临床意义

目的：探讨ICA、IAA、GAD—Ab、IA-2-Ab对糖尿病患者的检测及临床意义。方法：用ELISA法测定155例1型糖尿病患者和44例2型糖尿病患者以及32例正常人血清中的ICA、IAA、GAD—Ab、IA-2抗体。结果：1型糖尿病组和2型糖尿病组ICA的阳性率分别为36．8％和11．4％，IAA的阳性率分别为23．2％和16．0％，GAD—Ab的阳性率分别为58．7％和16．0％，IA-2-Ab的阳性率分别为20．0％和6．8％。结论：ICA、IAA、GAD—Ab、IA-2抗体对1型糖尿病的早期诊断及预测有重要的临床意义，且联合测定以上抗体能提高检出率，避免漏诊。     

3种自身抗体检测对1型糖尿病的诊断价值

绝大多数 1型糖尿病是因为胰岛B细胞自身免疫破坏而致胰岛素分泌绝对缺乏。在临床上又分急性起病 1型糖尿病和成人隐匿性自身免疫性糖尿病 (Lada)。本文对 94例1型糖尿病患者进行胰岛素自身抗体 (IAA)、胰岛细胞抗体(ICA)、谷氨酸脱羧酶抗体 (GAD Ab)检测 ,以了解 3种抗体检测对 1型糖尿病的诊断价值。材料与方法1　检测对象　安徽省立医院和合肥市第三人民医院内分泌科门诊住院 1型糖尿病患者 94例 ,按WHO诊断标准 ,其中男性 4 8例 ,女性 4 6例 ,平均年龄 31.4± 12 .8岁 (5～ 6 2岁 )。2　检测方法　IAA、ICA、GAD Ab采用德国宝…     

ROX参比荧光在实时荧光定量RT-PCR检测Nrf2mRNA中的应用

目的 建立大鼠Nrf2 mRNA实时荧光定量RT-PCR检测方法,评价ROX参比荧光在其分析中的归一化校正作用.方法 采用Taq Man探针法构建大鼠Nrf2 mRNA实时荧光定量RT-PCR检测方法;取大鼠混合cDNA的Nrf2 PCR产物,经凝胶电泳和测序鉴定反应特异性;取PCR标准品10个浓度梯度(2.0×109～2.0×100)各1份进行实时荧光定量RT-PCR检测,分析ROX参比荧光校正与否的标准曲线的线性范围的变化;取高、中、低值重组质粒样本各1份进行批内重复20次和批间连续20次实时荧光定量RT-PCR检测,分析ROX参比荧光校正与否的批内、批间重复性差异.结果 成功建立大鼠Nrf2 mRNA实时荧光定量RT-PCR检测方法;大鼠混合cDNA的Nrf2 PCR扩增片段与预期122 bp相符,测序结果扩增片段序列正确,PCR特异性好;标准品PCR扩增结果的标准曲线线性范围未经ROX参比荧光校正为2.0×109～2.0×102拷贝/μl(R2＞0.99),校正后为2.0×109～2.0×100拷贝/μl(R2＞0.99),校正后线性范围变宽100倍.高、中、低值样本重复性分析结果显示未经ROX参比荧光校正批内Ct变异系数(CV)为4.1%、2.7%、2.1%,批间CV为4.3%、3.0%、2.4%,校正后批内CV为0.7%、0.5%、0.4%,批间CV为1.0%、0.8%、0.7%,ROX参比荧光校正后样本Ct离散程度均低于未校正组,批内、批间的高值、中值浓度样本(高值组批内和批间t值分别为4.843、2.566,中值组批内和批间t值分别为4.293、4.423,P均＜0.05),但低浓度组的Ct离散度的差异无统计学意义(低值组批内和批间t值分别为0.753、1.279,P均＞0.05).结论 在构建大鼠Nrf2实时荧光定量RT-PCR检测方法中,加入ROX参比荧光,可加宽PCR标准曲线的线性范围,提高检测重复性,为准确分析大鼠模型Nrf2 mRNA表达水平奠定了基础.     

斑点金免疫渗滤法检测谷氨酸脱羧酶抗体及临床应用

目的：探讨斑点金免疫渗滤法快速测定谷氨酸脱羧酶抗体在糖尿病患者中的临床应用价值。方法：采用斑点金免疫渗滤法（DIGFA）检测88例糖尿病患者和40例正常人群的血清谷氨酸脱羧酶抗体（GAD－Ab),并与酶联免疫吸附法（ELISA）作方法学的比较。结果：DIGFA法检测1型和2型糖尿病患者的血清GAD－Ab阳性率分别为61．3％和19．3％,有显著性差异（P＜0．01）,且均明显高于正常人群。与ELISA法比较,两种方法的检出率无显著性差异（P＞0．05）。结论：血清谷氨酸脱羧酶抗体在1型及有高度1型糖尿病倾向的人群中检出率较高,可作为糖尿病分型的依据,斑点金免疫渗滤法快速、简便、可靠、有实用价值。     

Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults.

BACKGROUND: The different clinical presentations of latent autoimmune diabetes in adults (LADA) and type 1 diabetes mellitus may be the result of susceptibility genes in determining the mode of onset. We analyzed the 5' polymorphisms of the insulin mini-satellite region (INS), a variable number of tandem repeats (VNTR) [repeat units; RU]. We evaluated the association of the different INS-VNTR alleles in patient susceptibility to LADA autoimmune diabetes. To our knowledge, this constitutes the first study of this kind performed in a Caucasian population. METHODS: From an group of 160 Argentinean patients previously characterized as having LADA, we selected 44 patients who presented with humoral autoimmunity for genotyping and compared them to 88 patients with type 1 diabetes and 138 healthy individuals. The INS-VNTR allele classes were determined by Southern blotting (class I: 21-44RU; class III: 138-159RU). Subjects with class I alleles were further studied using PCR amplification to determine the exact length of the alleles (short 1S: 22-37RU; medium 1M: 38-41RU; large 1L: 42-43RU). Allelic and genotype frequencies were estimated by chi(2) tests for independence with 2 x 2 contingency tables and the relative risks (RR) were determined using GraphPad InStat software. RESULTS: We observed differential associations among the class I alleles when comparing patients with LADA (80.6%) and type 1 diabetes (81.3%) with the controls (70%; p < 0.005). This increase was largely due to the high frequency of the 1S/S genotype (63.6% LADA vs 37% controls, with a p-value of 0.0019 [p1]; 53.4% type 1 diabetes vs 37% controls, with a p-value of 0.0149 [p2]). Remarkably, all LADA patients genotyped as class I homozygous had the shorter (S) class I allele (100%). Differences in the overall 1S distribution were observed: in LADA the 94.4% of the alleles were equal to or smaller than 35RU, while in patients with type 1 diabetes it was 78.3% and in controls 74.1%. Moreover, the relative risks associated with the 1S/S genotype for patients with LADA showed a substantial increase with respect to those with type 1 diabetes (52%) when we compare them to the controls (1S/S LADA/control, 2.282 [RR1] vs type 1 diabetes/control, 1.497 [RR2]). CONCLUSION: The presence of the 1S allele could be considered a risk factor in LADA patients, as previously reported for type 1 diabetes. The class I INS-VNTR allele in LADA increases genetic susceptibility to disease development.     

免疫透射比浊法测定血清RBP的方法学及临床价值初步评价

目的对免疫透射比浊法测定血清视黄醇结合蛋白（RBP）进行方法学和临床应用评价。方法用免疫透射比浊法测定62例肾病患者（肾小球肾炎35例、糖尿病肾病14例、慢性肾功能衰竭13例）、86例肝病患者（急性肝炎21例、肝硬化49例、肝恶性肿瘤16例）及100名健康体检者的血清RBP含量,根据美国临床实验室标准化委员会（NCCLS）相关文件对其进行精密度、线性、准确度等方法学评价以及临床应用初探。结果免疫透射比浊法的批内变异系数（CV）为2.05%~4.35%,批间CV为2.94%~5.41%,总CV为2.71%~8.85%。线性不低于120 mg/L,回归方程为Y=0.934X＋4.838,r=0.975。最低检测浓度为1 mg/L。低、中、高浓度回收率分别为109.5%、96.2%、98.8%,总回收率为99.4%。该法与DADE BEHRING特种蛋白仪的相关性良好（r=0.997）。肾病各组的血清RBP含量均高于健康对照组（P均〈0.01）,但肾病组内差异均无统计学意义（P〉0.05）。肝病各组的血清RBP含量均低于健康对照组（P均〈0.01）,肝病组内比较差异均无统计学意义（P〉0.05）。结论免疫透射比浊法简便、快速、灵敏、结果准确,可用全自动生化分析仪测试,宜于推广。RBP对肝、肾疾病的诊断都有临床意义。     

Hyperproinsulinemia segregates young adult patients with newly diagnosed autoimmune (type 1) and non-autoimmune (type 2) diabetes

OBJECTIVE: To investigate whether measurements of proinsulin and/or intermediate proinsulin degradation products could be used to differentiate between autoimmune (type 1) and non-autoimmune (type 2) diabetes in young adults. MATERIAL AND METHODS: Total proinsulin, intact proinsulin and 32,33 split proinsulin concentrations were measured in 25 patients aged 15-34 years with type 1 diabetes, as defined by the presence of at least two positive islet autoantibodies, and in 23 antibody-negative patients of similar age with type 2 diabetes, at the time of clinical onset of diabetes and at 3-4 months thereafter. Comparisons were made with data from 25 healthy subjects matched for gender and age. RESULTS: Plasma levels of total proinsulin, intact proinsulin and 32,33 split proinsulin were significantly increased 2-3-fold in the patients with newly diagnosed type 2 diabetes as compared with the controls, both in absolute terms (p<0.0001) and when related to circulating insulin (p<0.01-0.0002). In contrast, absolute proinsulin and 32,33 split proinsulin concentrations were significantly lower in patients with onset of type 1 diabetes than in controls. When proinsulin and split proinsulin release were related to plasma insulin, however, similar ratios were found in the type 1 diabetes patients and in controls. Using the 90th percentile for total proinsulin in the control group as the cut-off, the sensitivity and specificity for differentiation between autoimmune and non-autoimmune diabetes were 87% and 92%, respectively. At 3-4 months after clinical onset of diabetes, proinsulin secretion was still 2-3 times higher in type 2 than in type 1 diabetes patients (p<0.001). CONCLUSIONS: Young adult patients with newly diagnosed type 2 diabetes display disproportionate hyperproinsulinemia, whereas proinsulin secretion appears to be normal in patients with clinical onset of type 1 diabetes. Evaluation of proinsulin and 32,33 split proinsulin concentrations may be useful as a diagnostic tool in differentiating between autoimmune and non-autoimmune diabetes in young adults, particularly in those lacking islet autoantibodies at diagnosis.     

TCF7L2基因rs7903146多态性与2型糖尿病的相关性研究

目的探讨转录因子7样2(TCF7L2)基因rs7903146多态性与中国随州地区汉族人群2型糖尿病的相关性。方法选取已经确诊为2型糖尿病患者458例,其中男232例,女226例;空腹血糖<5.6 mmol/L,无其他系统性疾病的表现健康个体186名,其中男91名,女95名。测量研究对象的一般临床指标,糖代谢和脂代谢相关指标。应用聚合酶链反应(PCR)TaqManTM荧光探针技术进行等位基因分型,对2组共642例研究对象的TCF7L2基因rs7903146多态性进行分析。结果 TCF7L2基因rs7903146多态性符合Hardy-Weinberg平衡定律,TCF7L2基因rs7903146的C/C、C/T、T/T 3种基因型在2型糖尿病组中的频率分别为92.2%、7.6%和0.2%,在对照组的频率为92.5%、7.5%和0%,χ2检验发现,2组间差异无统计学意义。T等位基因频率在糖尿病组和对照组分别为4.0%、3.8%,经χ2检验差异无统计学意义。结论 TCF7L2 rs7903146多态性不是湖北随州地区的汉族人群中2型糖尿病的主要致病基因位点。     

Improving cardiovascular risk – applying evidence‐based medicine to glucose‐lowering therapy with thiazolidinediones in patients with type 2 diabetes

Background: The management of patients with type 2 diabetes aims to reduce the elevated risk of cardiovascular disease (CVD) by addressing established risk factors including hyperglycaemia, dyslipidaemia and hypertension. The thiazolidinediones are equally effective in improving glycaemic control when used in combination regimens in patients with type 2 diabetes, but have differing effects on the diabetic dyslipidaemia. Aims: To compare the effects of rosiglitazone and pioglitazone on inflammatory mediators associated with atherosclerosis and CVD, surrogate cardiovascular endpoints, and hard cardiovascular outcomes in patients with type 2 diabetes. Materials and methods: A search of the PubMed database plus manual search of referenced papers for other relevant citations. Results: Both glitazones reduce inflammatory markers and other circulating markers of CV disease. Available data suggest that pioglitazone can delay progression of atherosclerosis in patients with type 2 diabetes, as shown by the PERISCOPE and CHICAGO studies, and that it can reduce the rate of clinical CV events as shown by PROactive. Clinical end‐point data for rosiglitazone are inconclusive, providing no evidence of benefit and a possible increase in myocardial infarction. Discussion: There is a consistency of benefit with pioglitazone on markers, surrogate cardiovascular outcomes and clinical end‐point trials. Conclusion: Pioglitazone is the preferred thiazolidinedione to reduce cardiovascular risk in people with type 2 diabetes.     

Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum.

BACKGROUND: Surface-enhanced laser desorption-ionization time-of-flight (SELDI-TOF) mass spectrometry of human serum is a potential diagnostic tool in human diseases. In the present study, the preanalytical and analytical variation of SELDI-TOF mass spectrometry of serum was assessed in healthy individuals. METHODS: Serum and plasma were obtained from healthy human individuals. Protein peaks in human serum and plasma were determined by SELDI-TOF mass spectrometry. RESULTS: The protein peaks in serum in healthy individuals showed no variation with gender, age, fasting, or diurnal rhythm. The intensity of protein peaks changed significantly during clotting of serum from 30 to 60 min, followed by smaller changes from 60 to 120 min. The intensity of protein peaks changed after 60-min storage of serum at room temperature, whereas no changes were observed for storage on ice. The number of reproducible protein peaks in serum was determined on WCX2, SAX2, and IMAC30 arrays as 29, 34, and 36, respectively. The average coefficient of variation (CV) of the mass value of protein peaks was 0.03%. The intra-assay CV of peak intensity on IMAC30 arrays was 16% (10%-36%, n=8) for 36 peaks, inter-assay CV was 18% (6%-34%, n=4) for 16 peaks, and inter-individual CV was 38% (16%-56%, n=16) for 20 peaks. CONCLUSIONS: The pre-analytical and analytical conditions of SELDI-TOF mass spectrometry of serum have a significant impact on the protein peaks, with the number of peaks low and the assay variation high. Consequently, SELDI-TOF mass spectrometry of serum needs further evaluation before application in clinical diagnostics.     

Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes

BACKGROUND: Resistin is a recently identified adipocyte-secreted hormone in rodents, and has been proposed to serve as a link between obesity and insulin resistance. The aim of this study was to develop a sensitive enzyme-linked immunosorbent assay (ELISA) for human resistin and evaluate serum resistin concentrations in normal subjects and patients with type 2 diabetes. METHODS: Using ELISA developed by two polyclonal antibodies, resistin concentrations were measured in 90 patients with type 2 diabetes and compared to 74 healthy control subjects. RESULTS: This ELISA has high specificity and sensitivity over the concentration of range 0.5-100 ng/ml with good percentage recovery (97.1 +/- 4.7%) and reproducibility (within-day assay, CV = 4.8-8.6%; between-day assay, CV = 5.6-9.7%). The mean concentration of resistin in sera from type 2 diabetic patients was significantly higher than that in normal subjects (mean +/- S.E.: 20.8 +/- 0.7 vs. 14.9 +/- 0.5 ng/ml, p < 0.001). A moderate positive correlation was observed between serum resistin levels and body mass indices in both normal subjects (r = 0.412, p < 0.0003) and patients with type 2 diabetes (r = 0.395, p < 0.0001). CONCLUSIONS: Our ELISA will be useful to confirm the physiological and pathophysiological role of resistin in humans.